Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1467-1472

  Li, Xiao ^a   Ren, Hong ^a   Zhang, Qianying ^a   Zhang, Wen ^a   Wu, Xiaojing ^a   Xu, Yaowen ^a   Shen, Pingyan ^a   Chen, Nan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

induction therapy; lupus nephritis; mycophenolate mofetil; tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LIVER FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; OPEN STUDY; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859349351     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr484     Document Type: Article

References (32)

1. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus 2008; 17: 426-430 (Pubitemid 351798721)
2. Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus-what's hot and what's not! Rheumatology (Oxford) 2009; 48: 332-341
3. Karim Y, D'Cruz DP. The NIH pulse cyclophosphamide regime: the end of an era? Lupus 2004; 13: 1-3 (Pubitemid 38129343)
4. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
5. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084 (Pubitemid 41710318)
6. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228 (Pubitemid 41697285)
7. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504-510 (Pubitemid 41727277)
8. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112
9. Kondo H, Abe T, Hashimoto H et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004; 31: 243-251 (Pubitemid 38160744)
10. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford) 2006; 45: 441-444
11. Lampropoulos CE, Sangle S, Harrison P et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43: 1383-1385 (Pubitemid 39480924)
12. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942 (Pubitemid 47244763)
13. Chan TM. Mycophenolate mofetil in the treatment of lupus nephritis-7 years on. Lupus 2008; 17: 617-621
14. Mak A, Cheak AAC, Tan JYS et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009; 48: 944-952
15. Mok CC, Tong KH, To CH et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005; 68: 813-817 (Pubitemid 43323138)
16. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 2009; 19: 606-615
17. Najafi CC, Korbet SM, Lewis EJ et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163 (Pubitemid 32467607)
18. Sloan RP, Schwartz MM, Korbet SM et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 1996; 7: 299-305 (Pubitemid 26092479)
19. Balow JE, Austin HA. Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 2003; 23: 386-391 (Pubitemid 37022042)
20. Isenberg D, Appel GB, Contreras G et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010; 49: 128-140
21. Sceto CC, Kwan BCH, Lai FM et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology 2008; 47: 1678-1681
22. Haddad M, Lau K, Lavjay B. Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol 2007; 22: 1787-1791 (Pubitemid 47337438)
23. Duncan N, Dhaygude A, Owen J et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004; 19: 3062-3067 (Pubitemid 40057629)
24. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029-2034
25. Stallone G, Infante B, Gesualdo L. There is a choice for immunosuppressive drug nephrotoxicity: is it time to change? J Nephrol 2009; 22: 326-332
26. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508
27. Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782 (Pubitemid 34260577)
28. Flanc RS, Roberts MA, Strippoli GF et al. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208
29. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004; 13: 673-678 (Pubitemid 39279782)
30. Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat Clin Pract Rheumatol 2005; 1: 22-30
31. Jones RB, Walsh M, Smith KGC. What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis? Curr Opin Rheumatol 2009; 21: 256-261
32. Tanaka H, Oki E, Tsugawa K et al. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study. Lupus 2007; 16: 896-900 (Pubitemid 350157276)